B+
Bull case
0%
Probability
Target price
$82.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
CRSP
CRISPR TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Casgevy adoption is accelerating, pediatric expansion broadens the eligible population, and upcoming CTX310, CTX340, CTX460, and zugo-cel data create several potential re-rating points. Secondary coverage reported Q2 EPS of negative $0.94 versus a negative $1.10 consensus estimate and revenue of $10.2 million versus $7 million consensus.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +0.4.
What can break
Casgevy uptake may be constrained by reimbursement, manufacturing, treatment-center capacity, or Vertex execution.
Momentum
23
Value
41
Sentiment
77
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $59.00 · Bull $82.00 · Bear $38.00Analysis 2026-08-13; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-13 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $82.95
Why
Momentum23 · Δ7d -8.4
Value41 · Δ7d -0.1
Sentiment77 · Δ7d +0.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +0.4.
Contradictions & invalidation
- • Casgevy uptake may be constrained by reimbursement, manufacturing, treatment-center capacity, or Vertex execution.
- • Clinical, safety, regulatory, and enrollment risk across CTX310, CTX340, CTX460, and zugo-cel.
- • Casgevy commercialization remains dependent on Vertex-led execution, treatment capacity, reimbursement, and broader access.
Catalyst clock
2026-08-03
Q2 results and Casgevy expansion
Lead driver: Sentiment · See AI snapshot
Momentum
23
8% active weight
Current posture
7d trendImproving
Δ7d
-8.4
Δ21d
-52.3
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
77
45% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+8.8
Why this grade
Composite grade C. Momentum 23.0 / Value 40.6 / Sentiment 76.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-13. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$59.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$4.98B
Beta
1.72
Shares Out
96.69M
P/E (TTM) · Derived
-8.0
P/S (TTM)
137.09
P/FCF (TTM) · Derived
-13.15
Rev YoY
+1041.4%
EPS YoY
-60.6%
Gross Margin
-1510.7%
Op Margin
-3971.5%
Net Debt
-$1.78B
Current Ratio
17.85
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data